Albuquerque, NM – July 20, 2015 The U.S. Patent & Trademark Office (USPTO) recently issued eight patents during April, May and June for technologies invented at the University of New Mexico. The patents, issued during STC.UNM’s 2015 fiscal 4th quarter, are for a variety of technologies created by researchers in the Department of Pharmaceutical Sciences, Department of Electrical & Computer Engineering, Center for High Technology Materials, Department of Neurology, Department of Neurosciences, Department of Chemical & Biological Engineering, and the Center for Biomedical Engineering, Department of Internal Medicine, Division of Translational Informatics, Center for Molecular Discovery, Department of Pathology, and the Clinical & Translational Science Center.
Issued Patent: “ARG-GLY-ASP-conjugated Alpha-Melanocyte Stimulating Hormone Hybrid Peptide for use in Diagnosing and Treating Melanoma, including Metastatic Melanoma and Methods Related to Same”
This technology is currently optioned for licensing.
Patent No. 9,005,575, issued April 14, 2015
Inventors: Yubin Miao, Jianquan Yang
Malignant melanoma is the most lethal form of skin cancer and the most commonly diagnosed malignancy among young adults. Unfortunately, no curative treatment exists for metastatic melanoma. The present technology is a radio-labeled peptide probe that can specifically bind to a melanocyte stimulating hormone (MSH) receptor that is over-expressed on melanoma cells. Upon binding to the receptor, the probe can selectively deliver diagnostic or therapeutic radionuclides to melanoma tumor cells for imaging or therapy.
Issued Patent: “Conjugated Polyelectrolyte Capsules: Light-Activated Antimicrobials”
This technology is currently optioned for licensing.
Patent No. 9,005,540, issued April 14, 2015
Inventors: David Whitten, Kirk Schanze, Motokatsu Ogawa, Jonathan Robert Sommer, Thomas Corbitt
Microbes can linger on surfaces for at least a few hours and sometimes even days. Although standard disinfection protocols work well on cells in suspension, those that are attached to surfaces, which account for the majority of bacteria in the world, are notoriously resistant to standard disinfection protocols. This technology builds on an antimicrobial coating that has been developed by the same group of inventors that functions catalytically in a variety of environments using cationic conjugated polyelectrolytes (CPEs) to entrap and kill bacteria.
Issued Patent: “System and Methods for Generating Unclonable Security Keys in Integrated Circuits”
This technology is currently licensed.
Patent No. 9,030,226, issued May 12, 2015
Inventor: James Plusquellic, Ryan Helinski, Dhruva Acharyya
Many hardware security and trust mechanisms depend on the availability of a secret key or signature, which is a unique identifier that can be derived from each integrated circuit (IC). Conventional IC signatures are defined using digital data stored, such as in a flash drive, read-only memory (ROM), or a chip. Unfortunately, since the keys always remain in digital form, they are subject to an invasive attack by adversaries who may be able to extract the key. One method that can stop attacks on embedded digital keys is through physically unclonable functions (PUFs). This technology uses a uniquely modified PUF hardware circuit, which is based on the measured equivalent resistance variations in the power distribution system of an IC. This provides a signature key that is probabilistically unique and unclonable and can be used in next generation security at all levels.
Issued Patent for: “Methods for Reducing Superoxide Anions in Eukaryotic Organisms”
Patent No. 9,034,857, issued May 19, 2015
Inventors: Larry Sklar, William Burhans, Catherine Prudom Gineste, Christopher Allen, Oleg Ursu,
Anna Waller
Superoxide anions (O2-) are a form of reactive oxygen implicated in aging and age-related diseases in humans, including cancer, neurodegenerative disorders, cardiovascular disease and diabetes. Compounds that mimic the effects of caloric restriction could be therapeutically beneficial by inhibiting growth signaling. This technology is an assay for the detection and identification of caloric restriction mimetics that decrease superoxides in aging yeast (S. Cerevisiae).
Issued Patent for: “Superhydrophobic Aerogel That Does Not Require Per-Fluoro Compounds or Contain Any Fluorine”
Patent No. 9,040,435, issued May 26, 2015
Inventors: C. Jeffrey Brinker, David Kissel
The staggering costs of corrosion in steel infrastructures demonstrate a tremendous need for multifunctional coatings that can outperform traditional coatings. Most superhydrophobic coatings contain fluorine, which can be environmentally unfriendly and expensive. This technology is a method to produce a robust and inexpensive superhydrophobic material that does not contain per-fluoro compounds or fluorine, and can be applied as aerosol spraying, dip-coating, spin-coating, or blade casting.
Issued Patent for: “Light-Emitting Device Having Photon-Lifetime Modulation”
Patent No. 9,054,492, issued June 9, 2015
Inventors: Marek Osinski, Gennady Smolyakov
Increasing transmission rates at all levels of telecommunication networks and fiber-based RF photonic systems are raising the demand for very high-speed, low-cost, small optical transmitters with very high modulation bandwidths exceeding 100 GHz. This technology is a semiconductor, light-emitting device based on a whistle-geometry semiconductor ring laser (WRL) monolithically integrated with a distributed Bragg-reflector (DBR) master laser. The technology is expected to result in low-cost ultrafast (over 100 GHz) functional chips that are easy to use.
Issued Patent for: “Selective Efflux Inhibitors and Related Pharmaceutical Compositions and Methods of Treatment”
Patent No. 9,056,111, issued June 16, 2015
Inventors: Richard Larson, Larry Sklar, Bruce Edwards, Juan Strouse, Irena Ivnitski-Steele, Hadya Khawaja, Jerec Ricci, Jeffrey Aube, Jennifer Golden, Tuanli Yao, Warren Weiner, Chad Schroeder
Chemotherapy is currently one of the most effective ways to treat metastatic cancers. However, effective treatment is often impeded by the body’s defense mechanism to foreign intrusion, causing human multidrug resistance (MDR). Specifically, three major subfamilies (ABCB, ABCC, and ABCG) of the ABC transporter superfamily are related to MDR. This technology is for methods and novel compounds that inhibit these cancer-associated transporter proteins using novel inhibitors (pyrazolo[1,5-a]pyrimidine) that are selective toward ABCG2 over ABCB1.
Issued Patent for: “STEP-Derived Peptide for Brain Injury Treatment”
This technology is currently licensed.
Patent No. 9,068,172, issued June 30, 2015
Inventor: Surojit Paul
Cerebral stroke is the second most common cause of death worldwide. It is also a leading cause of long-term physical and mental disability in adults. For ischemic strokes, the most common drug used is a recombinant tissue plasminogen activator (t-PA), which breaks down the blood clot and increase chances of survival and recovery in some patients. But t-PA is not safe for everyone. This technology is a novel therapeutic for treatment of ischemic brain injury targeting tyrosine phosphatase STEP (also known as Ptpn5) that is active, resistant to degradation, crosses the blood-brain barrier and reduces brain infarct size and neurological deficits even when delivered 1.5 hours after the onset of ischemic stroke.
Source: STC.UNM
For more information, contact:
Denise Bissell
(505) 272-7310
dbissell@stc.unm.edu